Skip to main content
    J

    Jazz Pharmaceuticals PLC (JAZZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $239.77
    -1.78 (-0.74%)

    Market Cap: $15.50B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Jazz Pharmaceuticals PLC (JAZZ) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Jazz Pharmaceuticals (JAZZ) to earn $14.94 per share in the fiscal year ending Dec 31, 2026, on revenue of $4.80B. Of 22 analysts, 20 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 9 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 22 ratings average 1.77, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 91% of the ratings.

    RatingAnalystsShare
    Strong Buy731.8%
    Buy1359.1%
    Hold29.1%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    22

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 73.9% and revenue estimates rise 5.4%.

    Fiscal year ending Dec 31, 2026
    $14.94
    EPS consensus, revenue $4.80B
    Fiscal year ending Dec 31, 2027
    $25.98
    EPS consensus, revenue $5.06B
    Next report
    Feb 22, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$14.94$13.98 to $15.9719$4.80B$4.75B to $4.84B20
    Dec 31, 2027$25.98$13.70 to $32.1419$5.06B$4.75B to $5.29B21

    Quarterly Estimates

    The EPS consensus falls from $7.12 for the quarter ending Dec 31, 2026 to $5.89 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$7.12$5.19 to $13.3222$1.30B$1.20B to $1.39B20
    Mar 31, 2027$5.89$4.88 to $6.706$1.14B$1.12B to $1.17B4

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 6 upward and 14 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202609
    Fiscal year ending Dec 31, 202755
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 40.3% from $25.03.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$14.94$15.49$16.12$24.39$25.03-40.3%
    Fiscal year ending Dec 31, 2027$25.98$25.20$24.02$25.08$25.77+0.8%
    Quarter ending Mar 31, 2027$5.89$6.26$5.65$5.65$5.64+4.4%

    Frequently Asked Questions About JAZZ

    What is the JAZZ stock forecast?

    Consensus analyst estimates put Jazz Pharmaceuticals's EPS at $14.94 for the fiscal year ending Dec 31, 2026, on revenue of $4.80B. The consensus rating from 22 analysts is Buy.

    How do analysts rate JAZZ stock?

    Of 22 analysts covering Jazz Pharmaceuticals, 7 rate it Strong Buy, 13 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from JAZZ next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $14.94, with estimates from $13.98 to $15.97 from 19 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $25.98, with estimates from $13.70 to $32.14 from 19 analysts.

    What revenue do analysts expect from Jazz Pharmaceuticals next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $4.80B, with estimates from $4.75B to $4.84B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $5.06B, with estimates from $4.75B to $5.29B.

    How many analysts cover JAZZ?

    22 analysts rate Jazz Pharmaceuticals stock, and 19 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.